Recursion Pharmaceuticals, Inc. Chief Financial Officer Ben R. Taylor filed a Form 4 on November 18, 2026, disclosing that 25,018 shares of Class A Common Stock were withheld on November 16, 2026, to cover tax obligations arising from the net settlement of restricted stock units.

Key Highlights

  • Reporting person: Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
  • Transaction date: November 16, 2026
  • Shares withheld: 25,018 shares of Class A Common Stock, transaction code F
  • Price per share: $3.185
  • Beneficial ownership following transaction: 1,046,444 shares of Class A Common Stock, held directly
  • Purpose of withholding: To satisfy the issuer's tax withholding and remittance obligations in connection with RSU net settlement, per the filing's footnote

RSU Tax Withholding Transaction by Recursion Pharmaceuticals CFO

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Ben R. Taylor, the Chief Financial Officer of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), reported a single transaction involving Class A Common Stock on November 16, 2026. The filing records a disposition of 25,018 shares at a price of $3.185 per share, coded as an "F" transaction.

The filing's footnote explains that the reported shares "represent shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units." This type of transaction reflects a standard mechanism in which a company retains a portion of vesting RSU shares to cover the recipient's tax liability rather than requiring a separate cash payment. No open-market sale is indicated by the filing.

Following the reported transaction, the filing states that Taylor directly holds 1,046,444 shares of Class A Common Stock. The Form 4 was signed by Kyle Nelson as attorney-in-fact on November 16, 2026, and filed on November 18, 2026. Table II of the filing contains no derivative securities transactions.

What Was Disclosed

Recursion Pharmaceuticals CFO Ben R. Taylor disclosed the withholding of 25,018 Class A Common Stock shares at $3.185 per share on November 16, 2026, to satisfy tax obligations from an RSU net settlement, leaving him with direct beneficial ownership of 1,046,444 shares.